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Primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and chronic obstructive airway 
disease are characterized by neutrophilic inflammation in the lungs. In CF and chronic 
obstructive airway disease, improper functioning of neutrophils has been demonstrated. 
We hypothesized that the pulmonary damage in PCD might be aggravated by abnormal 
functioning neutrophils either as a primary consequence of the PCD mutation or second-
ary to chronic inflammation. We analyzed chemotactic responses and chemoattractant 
receptor expression profiles of peripheral blood neutrophils from 36 patients with PCD, 
21 healthy children and 19 healthy adults. We stimulated peripheral blood monocytes 
from patients and healthy controls and measured CXCL8 and IL-1β production with 
ELISA. PCD neutrophils displayed reduced migration toward CXCR2 ligands (CXCL5 
and CXCL8) in the shape change, microchamber and microslide chemotaxis assays, 
whereas leukotriene B4 and complement component 5a chemotactic responses were 
not significantly different. The reduced response to CXCL8 was observed in all subgroups 
of patients with PCD (displaying either normal ultrastructure, dynein abnormalities or 
central pair deficiencies) and correlated with lung function. CXCR2 was downregulated in 
about 65% of the PCD patients, suggestive for additional mechanisms causing CXCR2 
impairment. After treatment with the TLR ligands lipopolysaccharide and peptidoglycan, 
PCD monocytes produced more CXCL8 and IL-1β compared to controls. Moreover, PCD 
monocytes also responded stronger to IL-1β stimulation in terms of CXCL8 production. 
In conclusion, we revealed a potential link between CXCR2 and its ligand CXCL8 and 
the pathogenesis of PCD.
Keywords: chemokines, chemotaxis, cytokines, il-1, inflammation, neutrophils, pulmonary disease
inTrODUcTiOn
Primary ciliary dyskinesia (PCD) is a rare genetic disease, caused by abnormal structure and/or 
function of motile cilia (1, 2). Patients suffer from recurrent pulmonary infections that cause a 
decline in lung function over time, chronic upper airway symptoms, and almost half have laterality 
defects. Infections are the result of ineffective mucociliary clearance and could lead to a chronic 
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and non-resolving activation of the innate immune system. 
Particularly, neutrophilic granulocytes are abundantly present in 
PCD lungs (3).
In other chronic airway diseases characterized by neutro-
philic infiltrates, improper functioning of those phagocytes 
has been demonstrated (4, 5). The pulmonary damage in PCD 
might also be aggravated by abnormal functioning neutrophilic 
granulocytes. Indeed, in some old reports, the migratory capacity 
of peripheral blood neutrophils from patients with PCD (PCD 
PMN) toward N-formylmethionyl-leucyl-phenylalanine (fMLP), 
leukotriene B4 (LTB4) and complement component 5a (C5a) has 
been shown to be reduced (6, 7), whereas others reported unaf-
fected chemotaxis of PCD PMN to the bacterial peptide fMLP or 
rather aspecific stimuli, such as zymosan (8, 9).
Meanwhile, the various molecules and pathways contributing 
to the different steps in PMN extravasation and infiltration into 
inflamed lungs have been better characterized (10). In this study, 
we investigated chemotactic responses of PCD PMN to the CXC 
chemokines CXCL5 and CXCL8 that both activate the chemokine 
receptor CXCR2. In addition, CXCL8 functions through CXCR1 
as well, which is co-expressed on PMN with CXCR2 and CXCR4. 
We also tested LTB4 and C5a as chemotaxis inducers, which simi-
lar to chemokines, activate G protein-coupled receptors to guide 
phagocytes to infected tissues. We evaluated migration of PMN 
from patients with PCD and healthy children and adults in the 
Neuro Probe microchamber chemotaxis assay. Afterward, PMN 
from patients that showed decreased migration in the Neuro 
Probe chemotaxis assay were studied in μ-slide chemotaxis and 
shape change assays. Furthermore, we evaluated whether PCD 
PMN have an aberrant chemoattractant receptor expression 
profile compared to healthy individuals. Finally, we measured 
CXCL8 production after treatment of PCD monocytes with 
inflammatory stimuli.
MaTerials anD MeThODs
Patients and healthy controls
Thirty-six patients with PCD (range 2–26  years, average age 
13  years; for details, see Table  1) were enrolled between 2012 
and 2016 at the university hospitals of KU Leuven. Patients were 
only included when they were clinically stable (no change in 
cough or sputum, no fever, no change in therapy for a period of 
at least 2 weeks, change in FEV1 < 10% since the last measure-
ment). The study protocol (S57236[ML11095]) was approved by 
the ethical committee of the university. All patients underwent 
a combination of diagnostic testing: all had abnormal ciliary 
activity after cell culture of nasal biopsies. Electron microscopy 
of the cilia showed outer dynein arm deficiency (Dynein) in 16, 
microtubular disarrangement with inner dynein deficiency and 
central pair abnormalities (CP) in 1, absence of the central pair 
in 2, ciliary aplasia in 1, and normal ultrastructure (NU) in 16 
patients. Genetic analysis confirmed disease causing mutations 
in 24 patients, did not provide evidence for mutations in seven 
patients and was not performed in five patients.
Because neutrophil migration needs to be performed with 
freshly isolated cells and because maximally two patients could be 
evaluated on the same day, we included in each experiment PMN 
from a healthy adult control. This study, thus, included two control 
groups: a pediatric control group (n = 21; range 4–18 years, aver-
age age 10 years) that corresponded best to the enrolled patients 
and an adult control group (n = 19; range 23–41 years; average 
age 29) because it was impossible to organize blood donations of 
healthy children and children with PCD on the same day. Healthy 
pediatric controls were included as there are no available data on 
pediatric values of neutrophil function and expression of recep-
tors in function of age. The healthy controls (or their parents) all 
signed informed consent and their blood samples were processed 
identically to those of the patients (same transport time, condi-
tions, and handling time).
cell isolation
Blood samples were collected in EDTA+ tubes. Peripheral blood 
granulocytes and peripheral blood mononuclear cells (PBMCs) 
were separated and isolated from whole blood by density gradi-
ent centrifugation as described (11). First, the blood sample was 
diluted with D-PBS (Lonza, Belgium) and gently layered on 
Ficoll-sodium diatrizoate (Lymfoprep, Axis-Shield PoC AS, Oslo, 
Norway). After centrifugation (400 × g, 30 min, 20°C, without 
break), PBMCs and plasma were separated (top layers) from the 
granulocytes and red blood cells (bottom layer). After collection, 
PBMCs were washed twice, counted in a hemocytometer and were 
then ready for use. The red pellet of neutrophils and erythrocytes 
was gently mixed with a starch solution (6% Dextran; Sigma) and 
the mixture was incubated for 30 min at 37°C to cause aggregation 
and sedimentation of the red blood cells. After a wash step with 
D-PBS, the residual red blood cells in the granulocyte prepara-
tion were removed by performing a hypotonic shock. After two 
additional wash steps, the neutrophilic granulocytes (>95% of 
the total granulocytic fraction) were counted in a hemocytometer 
and were then ready for use.
48-Well Micro chamber chemotaxis assay
Neutrophil migration toward CXCL5, CXCL8, LTB4, and C5a 
was measured in a 48-well micro chemotaxis chamber (Neuro 
Probe, Gaithersburg, MD, USA) as described (12). LTB4 and 
CXCL8 (72 AA) were bought from Peprotech (Rocky Hill, NY, 
USA), complement component C5a from Sigma (St. Louis, 
MO, USA) and CXCL5 from R&D Systems (Abingdon, UK). In 
every assay, a reference adult control (healthy member of the 
laboratory staff) was included in order to allow normalization. 
Migration of the PCD PMN was expressed relative to migra-
tion of the reference adult control. The same approach (i.e., 
standardization to the healthy adult control) was used to study 
the migration of PMN from healthy children. Before we tested 
the migration of neutrophils from patients with PCD, we first 
tested dose–response curves of healthy neutrophils to determine 
the optimal concentration of chemoattractant to be tested with 
patient cells.
Flow cytometry
Flow cytometry was used to compare the expression of chemo-
attractant receptors on PMNs of patients with PCD and healthy 
controls. PMNs {3 × 105 cells, diluted in FACS buffer [D-PBS + 2% 
TaBle 1 | Patient characteristics.
Patient TeM 
abnormality
genetic defect Situs 
inversus
Bronchiectasis WBc (/μl) crP  
(mg/dl)
FVc  
(% pred)
FeV1  
(% pred)
sputum culture chronic 
infection
antibiotics or ig azithromycin inhaled 
steroids
1 NU DNAH11 0 1 7,020 <0.3 97 91 – – – – –
2 NU DNAH11 1 1 7,650 <0.3 114 98 – – –, iv immunoglobulins + +
3 NU DNAH11 0 1 6,420 4.9 78 90 – – –, iv immunoglobulins + +
4 ODA DNAH5 0 1 6,840 2.4 96 76 – – – – +
5 CP + IDA CCDC40 0 1 4,640 0.3 66 38 – – + – +
6 ODA ND 0 1 ND ND 96 88 H. influenzae – – + +
7 NU CCDC65 0 1 ND 1.1 65 38 H. influenzae H. influenzae – + +
8 ODA DNAH5 1 1 9,880 1.9 73 64 P. aeruginosa P. aeruginosa – + +
9 ODA DNAAF1 0 0 9,500 <0.3 112 110 S. aureus – – – –
10 ODA DNAAF1 0 0 9,500 0.6 121 108 – – – – +
11 ODA DNAH5 0 1 9,140 1.8 122 111 S. aureus – – – –
12 ODA ND 0 0 6,160 <0.3 74 74 – – + – –
13 ODA ND 1 1 8,300 0.6 82 82 H. influenzae – – – –
14 CP RSPH4 0 ND 5,100 0.3 94 94
15 ODA ND 0 1 4,700 <0.3 78 78 H. influenzae – –, subcutaneous 
immunoglobulins
+ +
16 ODA DNAH5 0 1 7,380 1.6 103 103 S. pneumoniae – + – +
17 NU ND 0 1 5,100 2.1 71 71 S. aureus, M. catarrhalis – – – –
18 NU DNAH11 0 1 5,990 110 110 ND – – + –
19 NU DNAH11 1 1 9,540 0.3 82 82 – – – + –
20 NU DNAH11 0 0 7,570 0.3 ND ND P. aeruginosa, H. influenzae – + – –
21 NU DNAH11 1 1 6,080 2.4 93 93 – – – – –
22 ODA CCDC103 1 0 6,880 1.1 108 108 – – – – –
23 ODA ND 1 0 9,220 2 98 98 H. influenzae H. influenzae – – –
24 ODA DNAH5 1 0 17,240 1 113 113 – – – – +
25 NU DNAH11 0 1 7,300 0.3 108 108 – – – + +
26 NU HYDIN 0 1 6,310 3.2 72 72 S. aureus, M. catarrhalis,  
H. influenzae
H. influenzae – – –
27 NU DNAH11 0 1 7,300 <0.3 107 101 ND ND – + +
28 NU CCDC103 1 0 7,350 <0.3 ND ND ND – + – –
29 CP ND 0 1 ND ND 110 112 S. aureus ND ND ND ND
30 NU ND 0 0 ND ND 104 97 – ND ND ND ND
31 ODA ARMC4 1 1 ND ND 98 74 – ND ND ND ND
32 NU ND 1 1 ND ND 75 71 – ND ND ND ND
33 NU DNAH11 1 1 ND ND 86 91 S. aureus ND ND ND ND
34 Ciliary aplasia ND 0 0 ND ND 88 84 P. aeruginosa ND ND ND ND
35 ODA ND 1 0 ND ND 98 90 – ND ND ND ND
36 ODA ND 0 0 ND ND 110 112 – ND ND ND ND
Ultrastructural and genetic defects, clinical presentation (situs inversus, bronchiectasis, WBC (/μl) and CRP (mg/dl) concentrations in blood circulation, FVC (% pred), FEV1 (% pred), bacteria strains (Haemofilus influenzae, Moraxella 
catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae) isolated from sputum and chronic infection in airways) and applied treatment (antibiotics, azithromycin, immunoglobulins, and inhaled 
steroids) of the studied patients with PCD.
CP, central pair; CRP, C-reactive protein; FEV1 (% pred), forced expiratory volume in 1 s (predicted%); FVC (% pred), forced vital capacity (predicted%); IDA, inner dynein arm; Ig, immunoglobulins; ND, not determined; NU, normal 
ultrastructure; ODA, outer dynein arm; TEM, transmission electron microscopy; WBC, white blood cell count.
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Fetal Calf Serum (FCS)]} were stained with the following mono-
clonal antibodies: unlabeled anti-CXCR1, anti-CXCR2, and 
anti-C5aR; PE-labeled anti-CD16 and anti-BLT1. The cells were 
incubated with the antibodies for 30 min and afterward washed 
three times with FACS buffer. Cells incubated with unlabeled 
antibodies were subsequently stained with goat anti-mouse 
PE-labeled antibody and again incubated for 30 min on ice. After 
three additional washing steps, the cells were fixed with FACS 
buffer containing 0.4% paraformaldehyde. Cell suspensions were 
applied to a FACSCalibur flow cytometer (BD Biosciences) and 
the results were analyzed by CellQuest software (BD Biosciences). 
The FSC/SSC gate settings for PMN were verified with anti-CD16 
antibodies.
shape change assays
The morphological shape changes that PMNs rapidly undergo 
when stimulated with chemotactic stimuli were examined as 
described (12). 50  µl of shape change buffer (HBSS without 
calcium and magnesium; supplemented with 10  mM HEPES) 
or 50  µl in shape change buffer diluted chemokine was added 
in duplicate to a 96-well plate. Shape change buffer was used as 
negative control. After adding the PMNs to the plate (3 ×  104 
cells/50 μl), the cells were fixed with 100 µl/well 4% paraform-
aldehyde in shape change buffer at time points 0 and 1 min. For 
each condition, at least 200 cells/stimulus were microscopically 
(200× magnification) evaluated by an additional independent 
researcher who was blinded for the experimental conditions. We 
calculated the percentage of non-activated (perfectly round) cells 
and activated cells (showing cellular extensions and an irregular 
cell shape). Before we tested the activation of neutrophils from 
patients with PCD, we first tested dose–response curves of 
healthy neutrophils to determine the optimal concentration of 
CXCL5 and CXCL8 to be tested with patient cells.
μ-slide 2D chemotaxis assay
Via time-lapse microscopy, the μ-slide chemotaxis assay allows 
to study directionality, velocity, and total distance covered dur-
ing the migration of PMNs toward a concentration gradient of 
chemokines (13). A microfluidic chamber (μ-slide VI, IBIDI, 
München, Germany) was used to create a stable concentration 
gradient of CXCL8. PMNs of patients with PCD and adult con-
trols (3 × 106 cells/ml) were suspended in RPMI 1640 + 2 mM 
HEPES + 0.5% HSA (μ-slide chemotaxis buffer) and after injec-
tion of the cells in the channel, the microfluidic chamber was 
incubated at 37°C for 30 min to allow the PMNs to settle down. 
Perpendicular on the channel with the cells, a concentration gra-
dient of CXCL8 (200 ng/ml in μ-slide chemotaxis buffer) was cre-
ated. Every 90 s, a snapshot of the cells was made with an inverted 
microscope (10× phase-contrast objective; Zeiss Axiovert 200 M) 
for 2  h. Constant temperature (37°C) and CO2 concentration 
(5%) were maintained throughout the recording. Migration of 
20 randomly picked PMNs of each donor was tracked with the 
ImageJ manual tracking plug-in and data were analyzed with the 
IBIDI chemotaxis and migration tool. The optimal concentration 
of CXCL8 was determined in pilot experiments with healthy 
neutrophils.
induction experiments and cXcl8 
Measurements
Freshly isolated PBMCs (containing both lymphocytes and 
monocytes) were diluted in induction medium (2 ×  106 c/ml; 
RPMI 1640 + 2% FBS + 0.01% gentamycin) and seeded in 48-well 
plates. Cells were stimulated with 500 ng/ml lipopolysaccharide 
(LPS), 10 µg/ml peptidoglycan (PGN) or 100 ng/ml recombinant 
human IL-1β at 37°C and 5% CO2. After 24 h, the cell supernatants 
were collected and stored at −20°C. CXCL8 (14) and IL-1β (R&D 
Systems) concentrations in the cell supernatants, and known 
to be mainly produced by the monocytes, were determined by 
ELISA (detection limit 10 pg/ml CXCL8 and 5 pg/ml IL-1β). The 
IL-1β Duoset ELISA principally measures the active cytokine and 
is only marginally cross-reactive with pro-IL-1β, according to the 
manufacturer.
statistical analysis
Normal distribution of the data was verified by the D’Agostino & 
Pearson normality test. Since the results were not normally dis-
tributed, non-parametric statistical tests were performed. First, 
non-parametric one-way ANOVA (Kruskal–Wallis test) was 
performed and afterward pairwise comparisons (Mann–Whitney 
U test) were performed to detect statistical differences between 
two groups using GraphPad software (GraphPad Software Inc., 
La Jolla, CA, USA). Significant differences detected by the Mann–
Whitney U test are indicated on the figures and in the text. The 
chi-square test was applied to test whether receptor expression 
levels were more often reduced in patients compared to controls. 
Finally, Pearson correlation analysis was executed to assess a 
possible correlation between CXCR2 expression levels or CXCL8 
response and lung function. A p-value <0.05 was regarded statis-
tically significant.
resUlTs
Peripheral Blood neutrophils from 
Patients with PcD Display reduced 
chemotactic responses to cXcr2 
ligands
Increased CXCL8 levels were previously detected in PCD sputum 
(3, 15), but migration of PCD PMN toward CXC chemokines has 
not yet been investigated. Although PMN from some patients with 
PCD displayed increased migratory capacity in the Neuro Probe 
microchamber chemotaxis assay, overall PCD PMN showed 
reduced migration toward CXCL5 and CXCL8 (Figures  1A,B, 
respectively) compared to healthy PMN (p  =  0.0011 and 
p  =  0.0003, respectively), whereas migration toward LTB4 
and C5a was not altered (Figures  1C,D, respectively). Non-
normalized chemotaxis results for CXCL5 and C5a are shown in 
Figure S1 in Supplementary Material. In order to detect whether 
reduced chemokine-induced migration only occurred in a 
subset of patients, chemotactic responses to CXCL8 and CXCR2 
expression levels were displayed according to the structural 
cilium characteristics (NU, versus Dynein, versus CP) (Figure 2). 
Figure 2A shows that decreased migration to CXCL8 is observed 
FigUre 1 | The chemotactic responses of peripheral blood PMN from patients with primary ciliary dyskinesia (PCD) are significantly lower to CXCL5 and CXCL8, 
but are normal to leukotriene B4 (LTB4) and complement component 5a (C5a). PMN from patients with PCD, healthy children (Ped CO) and healthy adults (Ad CO) 
were added to Neuro Probe chemotaxis chambers to compare their migratory capacity. The chemotactic index (CI; average number of migrated cells in response to 
the chemoattractant divided by the average number of spontaneously migrated cells) was used to express the chemotactic response. The chemotaxis toward  
(a) CXCL5 (10 ng/ml), (B) CXCL8 (10 ng/ml), (c) LTB4 (10−8 M), or (D) complement component C5a (10 ng/ml) was expressed relative to the chemotactic potency 
of the PMN from the reference Ad CO that was included in each Neuro Probe chemotaxis chamber on the same day (%). Each dot represents a separate blood 
donor and the horizontal lines indicate the median value. The number of blood donors (n) in each experimental group is indicated below the x-axis of a figure. 
Statistical data analysis was performed using the Mann–Whitney U test (Ad CO versus PCD: **p < 0.01, ***p < 0.001; Ped CO versus PCD: $$p < 0.01).
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in all subgroups and that the patients with an abnormal central 
pair show apparently less variability. Our study group included 
three such patients and PMN from one patient were analyzed on 
three different dates in the Neuro Probe chemotaxis assay and by 
flow cytometry. The results for this patient were congruent for the 
three testing dates.
chemoattractant receptor expression  
on PcD neutrophils
Expression levels of CXCR1 (CXCL8 receptor) and CXCR2 
(CXCL5 and CXCL8 receptor) on PCD PMN and Ad CO, measured 
by flow cytometry, did not significantly differ (Figures  3A,B); 
CXCR2 levels on PCD PMN only tended to be lower (median 
relative expression level 72%; p = 0.3383 PCD versus Ad CO). 
CXCR2 was downregulated in about 65% of the PCD patients. 
We performed a chi-square test to evaluate whether the propor-
tion of individuals with a reduced CXCR2 expression differed 
between the PCD patients, on the one hand, and the healthy Ad 
CO or Ped CO, on the other hand. We defined three categories: 
<90, 90–110, and >110% CXCR2 expression level (relative to 
the reference Ad CO) and tested whether PCD patients and Ad 
COs were differently distributed (p = 0.11, chi-square test). Non-
normalized CXCR2 flow cytometry profiles of neutrophils are 
FigUre 2 | Chemotactic responses and chemoattractant receptor expression levels of primary ciliary dyskinesia (PCD) PMN following classification according to the 
diagnosed ultrastructural cilium defect. The obtained results of the chemotactic responses and CXCR2 expression levels were grouped for the three subclasses of 
patients: patients with normal ultrastructure (NU), dynein arm deficiencies (Dynein), and central pair abnormalities (CP) to detect a correlation between decreased 
migration and a certain ultrastructural cilium defect. The chemotactic response to CXCL8 of PMN from patients with PCD, healthy children (Ped CO) and healthy 
adults (Ad CO) was assessed in Neuro Probe chemotaxis chambers (a), while simultaneously the expression levels of CXCR2 were measured by flow cytometry  
(B). The chemoattractant receptor expression levels (mean fluorescence intensity) were normalized to the levels on PMN from the reference Ad CO (%). Each dot 
represents a separate blood donor and the horizontal lines indicate the median value. The number of blood donors (n) in each experimental group is indicated  
below the x-axis. Statistical data analysis was performed using the Mann–Whitney U test (Ad CO versus PCD: *p < 0.05; Ped CO versus PCD: $ p < 0.05).
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shown in Figure S2 in Supplementary Material. Expression levels 
of the C5a and LTB4 receptors, BLT1 and C5aR, were not statisti-
cally different (Figures 3C,D). We explored a possible correlation 
between CXCR2 expression and the clinical parameter forced 
expiratory volume in 1 s (FEV1) and CXCR2 expression and the 
clinical parameter forced vital capacity (FVC) of the patients. 
However, we found no correlation between these lung function 
parameters and CXCR2 expression, but FEV1 correlated with the 
chemotactic response to CXCL8 (Pearson correlation coefficient 
r = 0.43, p = 0.02) (Figure S3 in Supplementary Material). Finally, 
we did not detect a clear effect of chronic infection or drug treat-
ment on CXCR2 expression levels or CXCL8 response (data not 
shown). However, there was a big variability in disease severity, 
type of chronic infection, and treatment between the included 
patients.
confirmation of reduced PcD PMn 
responses to cXcl5 and cXcl8 in 
alternative activation assays
Subsequently, we microscopically analyzed changes in cell shape 
1 min after stimulation of PCD PMN with CXCL5 or CXCL8. 
Figures 4A,B show the response to CXCL5 (n = 5) and CXCL8 
(n = 7), respectively. Three out of five patients displayed a reduced 
response to CXCL5, whereas the PMN from all patients tested 
were less responsive to CXCL8 (p = 0.0478).
In a second round of experiments using time-lapse microscopy, 
we monitored during 120 min migration of PMN from patients 
that showed a reduced chemotactic response to CXCL8 in the 
Neuro Probe chemotaxis chamber. The Neuro Probe chemotaxis 
assay and flow cytometry (CXCR1/2 expression) were repeated 
FigUre 3 | Chemoattractant receptor expression levels on PMN from patients with primary ciliary dyskinesia (PCD) and healthy controls. Expression levels of  
(a) CXCR1, (B) CXCR2, (c) BLT1 [the leukotriene B4 (LTB4) receptor], and (D) C5aR on PMN from patients with PCD, healthy children (Ped CO) and healthy  
adults (Ad CO) were measured by flow cytometry. The chemoattractant receptor expression levels [mean fluorescence intensity (MFI)] were normalized to the levels 
on PMN from the reference Ad CO (%). Each dot represents the normalized MFI of one patient or healthy control and the horizontal lines indicate the median value. 
The number of blood donors (n) in each experimental group is indicated below the x-axis. No statistical differences in chemoattractant receptor expression levels on 
PMN from patients with PCD and healthy controls were detected (Mann–Whitney U test).
7
Cockx et al. PCD-neutrophils Display Reduced Chemotaxis toward CXCR2-ligands
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1126
in parallel with the μ-slide chemotaxis assay (Figure  5A). We 
observed that PCD PMN migrated more slowly and, therefore, 
covered shorter distances toward CXCL8 than Ad CO PMN 
(Figures 5B–D). The directionality of migration was comparable 
for control and PCD PMN (data not shown). The decreased 
chemotactic response was, however, not associated with defec-
tive spontaneous migration, because the mean accumulated 
distance in response to buffer stimulation was similar for control 
and PCD PMN, confirming published findings (7).
PBMcs from Patients with PcD Produce 
More cXcl8 and il-1β in response to 
stimulation with Bacterial Products
Finally, it is known that CXCL8 levels in PCD sputum are 
increased (3, 15). To test the hypothesis that this is due to 
overproduction of CXCL8 by PCD monocytes, we stimulated 
PCD PBMCs with several inflammatory mediators. The relative 
distribution of monocytes and lymphocytes in the PBMC fraction 
was similar in patients compared to healthy controls. On average, 
9.7 ±  0.8% (mean ±  SEM) CD14+ cells were present in PCD 
patients compared to 9.1 ± 0.6% (mean ± SEM) CD14+ cells in 
the Ad CO (p = 0.6933). All inducers tested stimulated produc-
tion of CXCL8 by monocytes from healthy controls and patients 
with PCD (Figures 6A,B). Exact, non-normalized cytokine levels 
are shown in Table 2. The highest production of CXCL8 (402 ng/
ml) was induced by LPS in PCD PBMCs. CXCL8 production after 
LPS treatment was significantly (p < 0.05) enhanced in PCD com-
pared to Ped CO (Figure 6A). Also PGN provoked higher CXCL8 
production by PCD monocytes compared to monocytes of Ad CO 
(323 and 260 ng/ml, respectively, p < 0.05), however, due to the 
number of individuals tested, this difference was not statistically 
significantly for PCD versus Ped CO (p = 0.0823) (Figure 6B). 
IL-1β stimulation also led to higher CXCL8 production by PCD 
FigUre 4 | PMN from patients with primary ciliary dyskinesia (PCD) show reduced activation in response to CXCL8 in the shape change assay. In the shape 
change assay, PMN from patients with PCD and adult controls (Ad CO) were activated in suspension by addition of (a) CXCL5 (50 ng/ml) or (B) CXCL8 (50 ng/ml) 
for 1 min. The changes in cell shape were evaluated microscopically and the percentage of activated cells (showing an irregular outline with protrusions) was 
determined. The solid lines connect the corresponding patient and adult control within one experiment. The number of blood donors (n) in each experimental  
group is indicated below the x-axis. Statistical data analysis was performed using the Mann–Whitney U test (Ad CO versus PCD: *p < 0.05).
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monocytes compared to both healthy control groups (75, 25, and 
15 ng/ml, respectively; not shown). Since IL-1β is an important 
CXCL8 inducer (16), we also measured IL-1β in the PBMC 
supernatants (Figures  6C,D). IL-1β production was higher in 
PCD compared to Ad CO upon LPS stimulation (16 and 7 pg/
ml for PCD and Ad Co, respectively; p < 0.01) (Figure 6C), but 
not upon PGN stimulation (Figure 6D). Thus, PCD monocytes 
produce more CXCL8 and IL-1β in inflammatory conditions and 
IL-1β provoked higher CXCL8 production by PCD monocytes in 
turn. The increased CXCL8 production can downregulate CXCR2 
expression and cause CXCR2 desensitization on PMN, provid-
ing an explanation for the reduced migration toward CXCL8. 
We must admit that not all patients showed reduced CXCR2 
levels. However, it has been shown that in some circumstances 
chemokine receptors, although being upregulated, transmit 
migratory responses less efficiently (17–19).
DiscUssiOn
Our study of the chemotactic response of PCD neutrophils to 
four chemoattractants, C5a, LTB4, and the chemokines CXCL5 
and CXCL8, can be motivated by multiple arguments. First, there 
is no consensus whether PCD neutrophils are affected in their 
migratory response, because both normal (8, 9) and decreased 
(6, 7) migration of PCD neutrophils has been reported in the 
past. Of note, chemokines were not included in those studies. 
In addition, it is known that chronic inflammation influences 
functioning of neutrophilic granulocytes in cystic fibrosis (CF) 
and chronic obstructive pulmonary disease (COPD). PCD 
and CF, though caused by completely different gene defects, 
share some phenotypical characteristics, i.e., an important 
neutrophilic infiltrate being present in the lungs, impaired 
mucociliary clearance and recurrent airway infections. It has 
been shown that neutrophil survival, metabolism, effector, and 
regulatory functions are affected in CF due to mutations in the 
CFTR gene, but also as a consequence of chronic inflammation 
(20). We here demonstrate that also PCD neutrophils display 
aberrant chemotactic activity. We observed that in contrast 
to normal migration to LTB4 and C5a, chemoattractants act-
ing early in the extravasation process, we observed reduced 
migration toward the CXCR2 ligands CXCL5 and CXCL8, 
which act later on in the cascade guiding neutrophils from 
the blood stream to the inflamed tissue (21). The importance 
of CXCR2 in pathological PMN recruitment to inflamed lungs 
is underlined by the extensive efforts put into development of 
CXCR2 antagonists as a therapeutic approach to prevent lung 
injury by neutrophils in, e.g., COPD and CF (22, 23). Indeed, 
during severe exacerbations of COPD, enhanced levels of 
CXCR2 mRNA were detected correlating with the presence of 
tissue neutrophils (24). Furthermore, acute lung injury patients 
with CXCL8 gene polymorphisms expressing higher levels of 
CXCL8 have more prolonged and extensive lung injury (25). 
On the other hand, it is long known that neutrophils are needed 
to efficiently cope with bacterial infections (26) and CXCL5 was 
indispensable in several mouse models of infection (27, 28). Thus, 
the recruitment and activation of neutrophils in the lungs must be 
well-balanced and tightly regulated. Finally, also CC chemokines 
contribute to neutrophil recruitment to injured lungs (26). 
A recent study reported that in acute respiratory distress syn-
drome (ARDS), CCL2, and CCL7 synergize with CXCL8 to 
promote neutrophil migration (29).
Today, about 35 genes are known to be mutated in PCD. 
Because neutrophils and leukocytes in general do not have motile 
cilia, only some of these genes (which have a role in the building-
up of motile cilia in the cytoplasm) are expressed in leukocytes. 
The genes mutated in the genotyped patients with PCD included 
FigUre 5 | Decreased chemotactic capacity of peripheral blood PMN from patients with primary ciliary dyskinesia (PCD) to CXCL8 in the μ-slide chemotaxis assay. 
PMN from five patients with PCD were added to μ-slide chemotaxis chambers to assess their migratory capacity toward CXCL8 (200 ng/ml) in comparison to PMN 
from a healthy adult individual (Ad CO = 100%). Per condition, trajectory paths from 20 randomly picked cells were analyzed and several parameters were 
calculated. (a) On the same day, the PMN were tested in the Neuro Probe chemotaxis assay and analyzed by flow cytometry for CXCR1 and CXCR2 expression. 
The mean Euclidian distance and velocity of PCD PMN, measured in the μ-slide chemotaxis assay, were normalized to the mean Euclidian distance and velocity  
of PMN from the reference adult control (%). These parameters were significantly lower compared to the Ad CO (p < 0.01). (B) Representative cell tracks of two 
patients and an adult control are shown. For each experiment, (c) the mean accumulated distance or (D) center of mass obtained for the patient and adult control 
are connected by a solid line. The number of blood donors (n) in each experimental group is indicated below the x-axis. Statistical data analysis was performed 
using the Mann-Whitney U test (*p < 0.05; **p < 0.01) (ND = not determined).
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in this study are not expressed in neutrophils. However, the 
genetic defect is not known in one-third of the included patients 
(Table  1). Therefore, we cannot rule out that in some patients 
chemotaxis is reduced as a primary consequence of the mutation 
in PCD genes, whereas in others the defect is a secondary effect 
due to chronic infection/inflammation.
To reveal the molecular cause of reduced responsiveness of 
PCD PMN to CXCL5 and CXCL8, we determined expression 
levels of the CXC chemokine receptors involved (CXCR2 for 
CXCL5 and CXCR1 and CXCR2 for CXCL8). CXCR1 levels were 
normal, but in many patients CXCR2 levels were reduced. Several 
mediators, such as TLR2 and TLR4 ligands and cytokines, are 
known to regulate CXCR2 expression on neutrophils with nitric 
oxide and G protein-coupled receptor kinases (GRKs) acting 
downstream (30–32). In sepsis patients, LPS induces expression 
of GRK2 and downregulation of CXCR2 (33). LPS-induced 
CXCR2 downregulation is blocked in phospholipase D2 knock-
out mice (34) demonstrating involvement of this phospholipase 
upstream of GRK2. Although some similarities between neutro-
phils from PCD and sepsis patients might be noticed, LTB4 and 
fMLP responses in patients with sepsis were also reduced (31). 
To assess whether altered chemotaxis responses were related to 
TaBle 2 | The non-normalized CXCL8 and IL-1β levels released by peripheral 
blood mononuclear cells (PBMCs) from adult controls (Ad CO), pediatric controls 
(Ped CO) and patients with primary ciliary dyskinesia (PCD).
cytokine 
measured
cXcl8 (mean ± seM)  
(ng/ml)
il-1β (mean ± seM)  
(pg/ml)
stimulus lPs Pgn lPs Pgn
Ad CO 175.4 ± 22.8 246.6 ± 27.5  7.4 ± 1.5 11.6 ± 2.7
Ped CO 123.9 ± 34.8 139.4 ± 16.3 11.1 ± 2.4  7.7 ± 1.8
PCD 203.0 ± 27.9 390.4 ± 60.9 15.7 ± 4.9 11.1 ± 2.7
LPS, lipopolysaccharide; PGN, peptidoglycan.
PBMCs were cultured and stimulated with LPS (500 ng/ml) or PGN (10 µg/ml) at 37°C for 
24 h. By sandwich ELISA, CXCL8, and IL-1β levels were measured in the supernatants.
FigUre 6 | Increased production of CXCL8 by peripheral blood mononuclear cells (PBMCs) from PCD patients in response to pro-inflammatory stimuli. PBMCs 
from patients with PCD, healthy children (Ped CO) and healthy adults (Ad CO) were cultured and stimulated with (a,c) lipopolysaccharide (LPS) (500 ng/ml) and 
(B,D) PGN (10 µg/ml) at 37°C for 24 h. By sandwich ELISA, (a,B) CXCL8 and (c,D) IL-1β levels were measured in the supernatants. The CXCL8 and IL-1β levels 
are expressed relative to the CXCL8 and IL-1β levels of the reference Ad CO (equal to 100%, not shown). Each dot represents a separate blood donor and the 
horizontal lines indicate the median value. The number of blood donors (n) in each experimental group is indicated below the x-axis. Statistical data analysis was 
performed using the Mann–Whitney U test (Ad CO versus Ped CO or PCD: *p < 0.05, ***p < 0.001; Ped CO versus PCD: $ p < 0.05).
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changes in granulopoiesis or in the maturity of circulating neu-
trophils, we analyzed CD16 and CD11b expression. We found 
no significant differences in expression of both markers between 
the adult controls and the patients with PCD (CD16 expres-
sion (mean ± SEM) on neutrophils of PCD relative to Ad CO: 
114.0 ± 9.8%, p = 0.1968; CD11b expression (mean ± SEM) on 
neutrophils of PCD relative to Ad CO: 152.4 ± 25.3%, p = 0.3890).
Remarkably, the expression levels of CXCR2 varied greatly 
between the studied patients (Figure  3), though the reduced 
response to CXCL8 was observed more consistently. Upregulation 
of CXCR2 in some patients, versus downregulation in others, 
might relate to different degree of pathology or stage of disease or 
to a different pulmonary microenvironment. However, increased 
chemokine receptor expression does not exclude reduced respon-
siveness. Indeed, enhanced levels of CCR1 and CCR5 were shown 
to be present on monocytes from hemolytic uremic syndrome 
(HUS) patients, but HUS monocytes did not respond as well as 
monocytes from healthy individuals in functional assays (18). 
Also in patients with COPD, more monocytes expressed CCR5 
as a result of enhanced IL-6/sIL-6R expression, whereas less 
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monocytes migrated toward sputum supernatant compared to 
non-smokers (19). D’Amico et al. demonstrated that IL-10 treat-
ment upregulates chemokine receptors on monocytes, but those 
receptors are not coupled anymore to the classic signal transduc-
tion pathways and act as functional decoys (35).
One could argue that this study is lacking a disease control 
to examine whether our findings are specific for PCD. Pediatric 
patients with CF are not suited as disease control, because muta-
tions in the CFTR gene disturb neutrophil function (5). Patients 
with non-CF bronchiectasis also establish neutrophilic airway 
disease, but this group is so heterogeneous and some patients 
with unknown underlying immune deficiency could in this way 
be included. Asthma is rather an eosinophilic disorder, and has a 
completely different pathophysiology. Therefore, we believe that 
inclusion of an appropriate disease control group is not feasible. 
Moreover, our experimental set-up (chemotaxis assays) is very 
labor intensive and only a limited number of donors can be 
processed at a time.
Our results suggest that in patients with PCD decreased 
migration of peripheral blood PMN toward CXCL5 and CXCL8 
might contribute to inefficient clearance of pathogens from the 
airways. It is unclear whether this defect is primary or acquired. 
The defective response might be caused by desensitized CXCR2 
receptors due to constantly enhanced CXCL8 production in 
the airways. Indeed, we have shown here that PCD monocytes 
produce more CXCL8 and IL-1β, an important CXCL8 inducer, 
than healthy monocytes in response to inflammatory triggers. 
In addition, increased CXCL8 levels were reported in the sputum 
of patients with PCD (3, 15). On the other hand, since there is 
no apparent correlation between defective migration and type or 
severity of lung infection and inflammation (as expressed by age, 
infecting pathogen, severity of lung function, or structural lung 
disease as assessed by imaging; see Table 1), we cannot exclude 
an inherent PMN defect.
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